1192479-35-8

Basic information

• Product Name: 2-CHLORO-5-FLUORO-4-METHOXY-6-METHYLPYRIMIDINE
• Synonyms: 2-CHLORO-5-FLUORO-4-METHOXY-6-METHYLPYRIMIDINE
• CAS NO: 1192479-35-8
• Molecular Formula: C₆H₆ClFN₂O
• Molecular Weight: 176.5760432
• Mol File: 1192479-35-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 278.4±35.0 °C(Predicted)
• Appearance: /
• Density: 1.334±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.33±0.39(Predicted)
• CAS DataBase Reference: 2-CHLORO-5-FLUORO-4-METHOXY-6-METHYLPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-5-FLUORO-4-METHOXY-6-METHYLPYRIMIDINE(1192479-35-8)
• EPA Substance Registry System: 2-CHLORO-5-FLUORO-4-METHOXY-6-METHYLPYRIMIDINE(1192479-35-8)

Safety Data

• Hazardous Substances Data: 1192479-35-8(Hazardous Substances Data)

Usage

General Description

2-CHLORO-5-FLUORO-4-METHOXY-6-METHYLPYRIMIDINE is a chemical compound with the molecular formula C6H6ClFN2O. It is a pyrimidine derivative with a chlorine atom attached to the second carbon, a fluorine atom at the fifth carbon, a methoxy group at the fourth carbon, and a methyl group at the sixth carbon. 2-CHLORO-5-FLUORO-4-METHOXY-6-METHYLPYRIMIDINE is commonly used in the pharmaceutical industry for its potential biological activities, including antiviral and anticancer properties. It is also used as a building block in the synthesis of various drug candidates. However, it is important to handle this chemical with caution, as it may pose health hazards if not used properly.

Upstream product

• 67-56-1 methanol 
• 954220-98-5 2,4-dichloro-5-fluoro-6-methyl-pyrimidine 
• 124-41-4 sodium methylate 

Downstream Products

• 1192495-27-4 4-(bromomethyl)-2-chloro-5-fluoro-6-methoxypyrimidine 
• 1539318-26-7 N,N-di-tert-butyloxycarbonyl-(4aR,7aS)-6-(5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)-7a-(2-fluorophenyl)-4,4a,5,6,7,7a-hexahydropyrrolo[3,4-d][1,3]thiazin-2-amine 
• 1539318-27-8 N,N-di-tert-butyloxycarbonyl-(4aS,7aR)-6-(5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)-7a-(2-fluorophenyl)-4,4a,5,6,7,7a-hexahydropyrrolo[3,4-d][1,3]thiazin-2-amine 
• 1539316-78-3 (4aR,7aS)-6-(5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)-7a-(2-fluorophenyl)-4,4a,5,6,7,7a-hexahydropyrrolo[3,4-d][1,3]thiazin-2-amine 
• 1192494-30-6 (4aR,7aS)-6-(5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)-7a-(4-fluorophenyl)-2-imino-3-methylhexahydro-1H-pyrrolo[3,4-d]-pyrimidin-4(4aH)-one 

Relevant articles and documents

Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates

We describe successful efforts to optimize the in vivo profile and address off-target liabilities of a series of BACE1 inhibitors represented by 6 that embodies the recently validated fused pyrrolidine iminopyrimidinone scaffold. Employing structure-based design, truncation of the cyanophenyl group of 6 that binds in the S3 pocket of BACE1 followed by modification of the thienyl group in S1 was pursued. Optimization of the pyrimidine substituent that binds in the S2′-S2″ pocket of BACE1 remediated time-dependent CYP3A4 inhibition of earlier analogues in this series and imparted high BACE1 affinity. These efforts resulted in the discovery of difluorophenyl analogue 9 (MBi-4), which robustly lowered CSF and cortex Aβ40 in both rats and cynomolgus monkeys following a single oral dose. Compound 9 represents a unique molecular shape among BACE inhibitors reported to potently lower central Aβ in nonrodent preclinical species.

BACE INHIBITORS

The present invention provides compounds of Formula I useful as BACE inhibitors in the treatment of e.g. Alzheimer's disease : wherein A is selected from the group consisting of; of; R1 is H or F; R2 is H, -OCH3, C1-C3 alkyl,; R3 is H, -CH3, or -OCH3; and R4 is H or F; or a pharmaceutically acceptable salt thereof.

THIOPHENYL-SUBSTITUTED 2-IMINO-3-METHYL PYRROLO PYRIMIDINONE COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE

In its many embodiments, the present invention provides provides certain thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidone compounds, including compounds (or tautomers or a pharmaceutically acceptable salts thereof) having the structural Formula (III): wherein R2, R3, R4, R5, R6, R7, R8, and R9 are each selected independently and as defined herein. Pharmaceutical compositions comprising one or more such compounds, and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's Disease, are also disclosed.